Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models

During the development of indazolylpyrimidines as novel and potent inhibitors of vascular endothelial growth factor (VEGF) receptor-2 (VEGFR2) tyrosine kinase, we observed that some human tumour xenografts are more sensitive to VEGFR2 kinase inhibitors than others. A better understanding of the basi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dev, I K, Dornsife, R E, Hopper, T M, Onori, J A, Miller, C G, Harrington, L E, Dold, K M, Mullin, R J, Johnson, J H, Crosby, R M, Truesdale, A T, Epperly, A H, Hinkle, K W, Cheung, M, Stafford, J A, Luttrell, D K, Kumar, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409895/
https://www.ncbi.nlm.nih.gov/pubmed/15328520
http://dx.doi.org/10.1038/sj.bjc.6602109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409895/
https://www.ncbi.nlm.nih.gov/pubmed/15328520
http://dx.doi.org/10.1038/sj.bjc.6602109

Ejemplares similares